Participants
Deal Summary
Catalio Capital has closed its fourth fund, Fund IV, at over $400 million to continue investing in early-stage life sciences and biotech companies. The new fund will support the firm's existing strategy of backing founders in therapeutics and platform technologies.
Comments
Want to join the conversation?
Loading comments...